CAMBRIDGE, 11 September 2017 | CMR Surgical, the British company developing the next generation surgical robot, is pleased to announce the appointment of Steve Bell as its Commercial Director.
Steve brings to CMR over 25 years of surgical device commercialisation experience, securing a number of medical technology patents and trademarks throughout his career. He has commercialised some of the most recognised surgical brands including in laparoscopy, general surgery, cardiovascular, gynaecology and orthopaedics.
Steve joins the executive team of CMR from surgical implant company, RTI Surgical, where he accelerated the launch and commercialisation of critical new products for RTI’s surgical specialities business. He has had a long and successful career with Johnson & Johnson in their Endo surgery, Cardiovascular and Women’s Health divisions, before working for various Californian start-ups and mid-sized medical device companies, including 10 years at Insightra Medical.
Commenting on his new role, Steve Bell, Commercial Director, CMR said: “I’m delighted to be part of the single, most exciting medical technology company there is – a company that is going to revolutionise surgery and make a real difference for patients. Having done a lot of work in the United States, I’m thrilled to be working for a British company alongside some of the brightest minds in the industry.”
Commenting on the appointment, Martin Frost, Chief Executive Officer, CMR said:
“The breadth of Steve’s global experience bringing innovative new products to market is an invaluable asset to our fast growing, highly-skilled team. His expertise, from decades working in the medical devices industry, will help us achieve our ambitious target – to be one of the largest surgical robot companies internationally in five years with a robot in every major hospital.”
Notes to Editors:
About CMR Surgical
CMR Surgical is a private company developing the next-generation universal robotic system for minimal access (or “keyhole”) surgery.
The vision behind CMR is to make minimal access surgery universally accessible and affordable by significantly expanding the range of procedures that can be performed robotically. This will transform the existing market for surgical robotics.
Global annual revenues for robot-assisted minimal access surgery are presently approximately $4 billion and are anticipated to reach $20 billion by 2025.
CMR Surgical was formed in 2014 and has its headquarters in Cambridge, United Kingdom. The company achieved the registration of its Quality Management System to ISO 13485:2003 by Underwriters Laboratories LLC® (‘UL’), and the status as a UL Registered Firm, in September 2015.
Investors in CMR Surgical include ABB Technology Ventures, LGT Global, Cambridge Innovation Capital and Escala Capital.
For further information, please visit: www.cmrsurgical.com
 Industry Forecast, Accuray Research